KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Net Margin (2017 - 2025)

Bionano Genomics' Net Margin history spans 7 years, with the latest figure at 115.41% for Q3 2025.

  • For Q3 2025, Net Margin rose 61316.0% year-over-year to 115.41%; the TTM value through Sep 2025 reached 134.36%, up 27299.0%, while the annual FY2024 figure was 363.98%, 27976.0% up from the prior year.
  • Net Margin for Q3 2025 was 115.41% at Bionano Genomics, down from 101.86% in the prior quarter.
  • Across five years, Net Margin topped out at 48.04% in Q1 2025 and bottomed at 1208.05% in Q3 2023.
  • The 5-year median for Net Margin is 440.51% (2022), against an average of 416.07%.
  • The largest annual shift saw Net Margin crashed -76754bps in 2023 before it surged 61316bps in 2025.
  • A 5-year view of Net Margin shows it stood at 364.15% in 2021, then dropped by -29bps to 470.81% in 2022, then grew by 13bps to 409.39% in 2023, then skyrocketed by 40bps to 246.54% in 2024, then soared by 53bps to 115.41% in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Net Margin are 115.41% (Q3 2025), 101.86% (Q2 2025), and 48.04% (Q1 2025).